Naftali Bennett joins as a director the REMEPY startup company of Michal Tzur, his former partner from Sayota. The new company operates in the field of digital health and for the first time integrates software into medicines.
The REMEPy company leads a vision of hybrid medicines, which include a dedicated digital application that improves the effect of the medicine. The effects that the company has already demonstrated have the potential to influence medical outcomes in neurological diseases, cancer, autoimmune diseases and degenerative eye diseases.